FC
DGX icon

Financial Consulate’s Quest Diagnostics DGX Stock Holding History

Financial Consulate’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96K Buy
10
+2
+25% +$389 ﹤0.01% 986
2025
Q4 		$1.39K Hold
8
– – ﹤0.01% 958
2025
Q3 		$1.52K Buy
+8
New +$1.42K ﹤0.01% 818

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Financial Consulate's DGX Position: Q1 2026 in Review

Financial Consulate increased its Quest Diagnostics (DGX) stake by 25% in Q1 2026, buying an estimated $389 and bringing the position to 10 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #986.

Financial Consulate first reported a position in DGX in Q3 2025 and has held it in 3 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Financial Consulate held 10 shares of Quest Diagnostics worth $1.96K as of Q1 2026.
  • Financial Consulate bought 2 Quest Diagnostics shares in Q1 2026, an estimated $389.
  • Quest Diagnostics made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #986 holding.
  • Financial Consulate first reported a position in Quest Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.